ACCED, The Medication Safety Robot that Has Dominated the French Market for Ten Years, Continues Its Record-Breaking Commercial Expansion
27.4.2023 07:00:00 EEST | Business Wire | Press release
Deenova, Europe's leading provider of hospital pharmacy automation unit dose medication solutions, announced today the award of two competitive UniHA tender in France for three of its market-leading solution ACCED, with Drôme Vivarais hospital in Montéléger and St-Marcellin hospital.
The ACCED mechatronics solution, which is already in use in over 60 French hospitals, is a fully automated system that allows for the preparation and dispensing of oral solid medications in unit dose. It is intended to improve patient safety, reduce medication errors, and maximize operational efficiency while providing secure and dependable medication preparation and dispensing processes. Furthermore, the solution includes a reporting and analytics platform that provides hospitals with data-driven insights to improve operational performance.
Commenting on the news, Mr. Loic Bessin, Managing Director of Deenova France, said: "We are thrilled to be extending our automated unit dose medication solutions to Drôme Vivarais and St-Marcellin hospitals in France. Our D3 ACCED mechatronic robot is designed specifically to ensure complete patient safety, operational effectiveness, and financial viability. We are confident that both hospitals and their patients will benefit greatly from our solution. "
The St-Marcellin Hospital is a healthcare institution that provides a public service mission of care and accommodation, combining proximity and a recognized level of technicality in the activities of medicine, rehabilitation care and elderly care.
Opened in 1976, the Centre Hospitalier Drôme Vivarais (formerly known as the "Centre Hospitalier Le Valmont") is a public health establishment specialising in child and adult psychiatry, located in the commune of Montéléger, just a few kilometres from Valence.
It manages 240 beds on a hospitalization site, 11 Day Hospitals and 17 Medical-Psychological Centres, including 11 Part-time Therapeutic Reception Centres spread over 11 towns in the area.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
For more information on Deenova’s market-leading solutions, visit www.deenova.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005604/en/
Contact information
Christophe Jaffuel, c.jaffuel@deenova.com,
Martina Buccianti, m.buccianti@deenova.com, +39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 17:05:00 EET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 16:00:00 EET | Press release
ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer at ViTAA Medical said: “The SVS deserves credit for its foresight in embracing advances in AI, digital healt
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 15:39:00 EET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 15:30:00 EET | Press release
Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specification that lets any payment provider add Klarna to AI agent checkout. “Agentic
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 12:05:00 EET | Press release
SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing on a rolling basis through December 2026. It takes SatSure’s total capital raised to INR 427 crore (c. USD 46 millio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
